132 related articles for article (PubMed ID: 37029039)
1. Financial toxicity of oral therapies in advanced prostate cancer.
Joyce DD; Dusetzina SB
Urol Oncol; 2023 Sep; 41(9):363-368. PubMed ID: 37029039
[TBL] [Abstract][Full Text] [Related]
2. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
Joyce DD; Sharma V; Jiang DH; Van Houten HK; Sangaralingham LR; Borah BJ; Kwon ED; Penson DF; Dusetzina SB; Tilburt JC; Boorjian SA
J Urol; 2022 Nov; 208(5):987-996. PubMed ID: 36094864
[TBL] [Abstract][Full Text] [Related]
4. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
5. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.
Olszewski AJ; Zullo AR; Nering CR; Huynh JP
J Oncol Pract; 2018 Apr; 14(4):e221-e228. PubMed ID: 29443649
[TBL] [Abstract][Full Text] [Related]
6. Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.
Joyce DD; Schulte PJ; Kwon ED; Dusetzina SB; Moses KA; Sharma V; Penson DF; Tilburt JC; Boorjian SA
J Urol; 2023 Aug; 210(2):290-298. PubMed ID: 37416955
[TBL] [Abstract][Full Text] [Related]
7. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
8. Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country.
Ting CY; Teh GC; Yu KL; Alias H; Tan HM; Wong LP
Support Care Cancer; 2020 Apr; 28(4):1703-1715. PubMed ID: 31292755
[TBL] [Abstract][Full Text] [Related]
9. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
10. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
[No Abstract] [Full Text] [Related]
11. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
Joyce DD; Qin X; Sharma V; Boorjian SA; Barocas DA; Dusetzina SB; Moses KA
J Urol; 2023 Sep; 210(3):447-453. PubMed ID: 37341420
[TBL] [Abstract][Full Text] [Related]
12. Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada.
de Oliveira C; Bremner KE; Ni A; Alibhai SM; Laporte A; Krahn MD
J Cancer Surviv; 2014 Mar; 8(1):9-20. PubMed ID: 23975612
[TBL] [Abstract][Full Text] [Related]
13. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
14. Out-of-Pocket Costs and Perceived Financial Burden Associated with Prostate Cancer Treatment in a Quebec Remote Area: A Cross-Sectional Study.
El-Haouly A; Lacasse A; El-Rami H; Liandier F; Dragomir A
Curr Oncol; 2020 Nov; 28(1):26-39. PubMed ID: 33704114
[No Abstract] [Full Text] [Related]
15. Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action.
Bhanvadia SK; Psutka SP; Burg ML; de Wit R; Dhillon HM; Gyawali B; Morgans AK; Goldstein DA; Smith AB; Sun M; Penson DF
Eur Urol Oncol; 2021 Jun; 4(3):396-404. PubMed ID: 33820747
[TBL] [Abstract][Full Text] [Related]
16. Financial hardship and psychosocial well-being and quality of life among prostate cancer survivors in the United States.
Yabroff KR; Zhao J; Chen MH; Hoque J; Arias G; Han X; Zheng Z
Urol Oncol; 2023 Sep; 41(9):380-386. PubMed ID: 37202329
[TBL] [Abstract][Full Text] [Related]
17. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
19. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
